UCB's Global Corporate Website

This section is intended for media and financial analysts

UCB Announces Registration of Domination and Profit Transfer Agreement Allowing Full Integration of Schwarz Pharma

Brussels (Belgium), July 13, 2007, 7:00 am CET - UCB announced today the registration in the commercial register in Germany of the Domination and Profit Transfer Agreement between its wholly owned subsidiary, UCB SP GmbH, and Schwarz Pharma AG, 87.6% of which is owned by UCB.

"This is wonderful news for the whole UCB Group and it is another important milestone to our building UCB into a next generation biopharma leader", said Roch Doliveux, CEO of UCB. "The registration allows us to move from the integration planning stage to full implementation in the most effective and efficient way possible. "

Shareholders of Schwarz Pharma will be informed within the next few days of the steps to be taken to take advantage of the cash compensation offer of € 104.60 per Schwarz Pharma share.

About UCB

UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing more than 8,500 people in over 40 countries, UCB achieved revenue of 2.5 billion euro in 2006. UCB is listed on the Euronext Brussels Exchange and owns 87.6% of Schwarz Pharma.



For further enquiries, please contact

Antje Witte

Corporate Communications & Investor Relations                       

Tel. +49 2173 48 1866

Asset Download

Stay up-to-date on the latest news and information from UCB